VERRICA PHARMACEUTICALS INC (VRCA) Fundamental Analysis & Valuation

NASDAQ:VRCA • US92511W2070

Current stock price

5.91 USD
+0.19 (+3.32%)
At close:
5.91 USD
0 (0%)
After Hours:

This VRCA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. VRCA Profitability Analysis

1.1 Basic Checks

  • In the past year VRCA has reported negative net income.
  • In the past year VRCA has reported a negative cash flow from operations.
  • In the past 5 years VRCA always reported negative net income.
  • In the past 5 years VRCA always reported negative operating cash flow.
VRCA Yearly Net Income VS EBIT VS OCF VS FCFVRCA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -37.95%, VRCA perfoms like the industry average, outperforming 42.93% of the companies in the same industry.
  • VRCA has a worse Return On Equity (-72.29%) than 60.21% of its industry peers.
Industry RankSector Rank
ROA -37.95%
ROE -72.29%
ROIC N/A
ROA(3y)-87.17%
ROA(5y)-72.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRCA Yearly ROA, ROE, ROICVRCA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • The Gross Margin of VRCA (90.33%) is better than 92.67% of its industry peers.
  • In the last couple of years the Gross Margin of VRCA has remained more or less at the same level.
  • VRCA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5YN/A
VRCA Yearly Profit, Operating, Gross MarginsVRCA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. VRCA Health Analysis

2.1 Basic Checks

  • VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VRCA has been increased compared to 1 year ago.
  • Compared to 5 years ago, VRCA has more shares outstanding
  • VRCA has a better debt/assets ratio than last year.
VRCA Yearly Shares OutstandingVRCA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
VRCA Yearly Total Debt VS Total AssetsVRCA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • VRCA has an Altman-Z score of -6.35. This is a bad value and indicates that VRCA is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of VRCA (-6.35) is worse than 70.16% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that VRCA is not too dependend on debt financing.
  • VRCA has a Debt to Equity ratio (0.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -6.35
ROIC/WACCN/A
WACC11.6%
VRCA Yearly LT Debt VS Equity VS FCFVRCA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

2.3 Liquidity

  • VRCA has a Current Ratio of 2.59. This indicates that VRCA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.59, VRCA is in line with its industry, outperforming 44.50% of the companies in the same industry.
  • VRCA has a Quick Ratio of 2.45. This indicates that VRCA is financially healthy and has no problem in meeting its short term obligations.
  • VRCA has a Quick ratio (2.45) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.45
VRCA Yearly Current Assets VS Current LiabilitesVRCA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. VRCA Growth Analysis

3.1 Past

  • VRCA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.45%, which is quite impressive.
  • Looking at the last year, VRCA shows a very strong growth in Revenue. The Revenue has grown by 370.22%.
  • The Revenue has been growing by 57.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)90.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.83%
Revenue 1Y (TTM)370.22%
Revenue growth 3Y57.94%
Revenue growth 5YN/A
Sales Q2Q%1380.23%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.50% on average over the next years. This is a very strong growth
  • VRCA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.85% yearly.
EPS Next Y6.65%
EPS Next 2Y30.71%
EPS Next 3Y30.83%
EPS Next 5Y35.5%
Revenue Next Year-28.36%
Revenue Next 2Y17.31%
Revenue Next 3Y35.48%
Revenue Next 5Y40.85%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
VRCA Yearly Revenue VS EstimatesVRCA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
VRCA Yearly EPS VS EstimatesVRCA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. VRCA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VRCA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRCA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRCA Price Earnings VS Forward Price EarningsVRCA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRCA Per share dataVRCA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as VRCA's earnings are expected to grow with 30.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.71%
EPS Next 3Y30.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VRCA Dividend Analysis

5.1 Amount

  • No dividends for VRCA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VRCA Fundamentals: All Metrics, Ratios and Statistics

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (4/15/2026, 8:25:25 PM)

After market: 5.91 0 (0%)

5.91

+0.19 (+3.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)05-11
Inst Owners30.16%
Inst Owner Change0%
Ins Owners28.03%
Ins Owner Change11.79%
Market Cap101.53M
Revenue(TTM)35.58M
Net Income(TTM)-17.89M
Analysts81.82
Price Target16.83 (184.77%)
Short Float %5.68%
Short Ratio3.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)69.43%
Min EPS beat(2)43.23%
Max EPS beat(2)95.64%
EPS beat(4)3
Avg EPS beat(4)60.27%
Min EPS beat(4)-0.55%
Max EPS beat(4)102.78%
EPS beat(8)5
Avg EPS beat(8)28.3%
EPS beat(12)7
Avg EPS beat(12)16.01%
EPS beat(16)10
Avg EPS beat(16)23.08%
Revenue beat(2)2
Avg Revenue beat(2)75.51%
Min Revenue beat(2)10.31%
Max Revenue beat(2)140.71%
Revenue beat(4)4
Avg Revenue beat(4)94.11%
Min Revenue beat(4)10.31%
Max Revenue beat(4)191.87%
Revenue beat(8)6
Avg Revenue beat(8)27.8%
Revenue beat(12)9
Avg Revenue beat(12)71.01%
Revenue beat(16)11
Avg Revenue beat(16)55.88%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)6.73%
EPS NQ rev (3m)6.73%
EPS NY rev (1m)-13.79%
EPS NY rev (3m)-13.79%
Revenue NQ rev (1m)-17.86%
Revenue NQ rev (3m)-24.59%
Revenue NY rev (1m)-10.63%
Revenue NY rev (3m)-5.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.85
P/FCF N/A
P/OCF N/A
P/B 4.1
P/tB 4.1
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.37
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS2.07
BVpS1.44
TBVpS1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -37.95%
ROE -72.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.33%
FCFM N/A
ROA(3y)-87.17%
ROA(5y)-72.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5YN/A
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.59
Quick Ratio 2.45
Altman-Z -6.35
F-Score6
WACC11.6%
ROIC/WACCN/A
Cap/Depr(3y)22.88%
Cap/Depr(5y)100.39%
Cap/Sales(3y)2.47%
Cap/Sales(5y)3.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.83%
EPS Next Y6.65%
EPS Next 2Y30.71%
EPS Next 3Y30.83%
EPS Next 5Y35.5%
Revenue 1Y (TTM)370.22%
Revenue growth 3Y57.94%
Revenue growth 5YN/A
Sales Q2Q%1380.23%
Revenue Next Year-28.36%
Revenue Next 2Y17.31%
Revenue Next 3Y35.48%
Revenue Next 5Y40.85%
EBIT growth 1Y81.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-138.48%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y71.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.07%
OCF growth 3YN/A
OCF growth 5YN/A

VERRICA PHARMACEUTICALS INC / VRCA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VERRICA PHARMACEUTICALS INC (VRCA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VRCA.


What is the valuation status of VERRICA PHARMACEUTICALS INC (VRCA) stock?

ChartMill assigns a valuation rating of 1 / 10 to VERRICA PHARMACEUTICALS INC (VRCA). This can be considered as Overvalued.


What is the profitability of VRCA stock?

VERRICA PHARMACEUTICALS INC (VRCA) has a profitability rating of 1 / 10.


Can you provide the financial health for VRCA stock?

The financial health rating of VERRICA PHARMACEUTICALS INC (VRCA) is 3 / 10.


Can you provide the expected EPS growth for VRCA stock?

The Earnings per Share (EPS) of VERRICA PHARMACEUTICALS INC (VRCA) is expected to grow by 6.65% in the next year.